Secondary analysis of Magnolia trial in myeloma: in patients with at least VGPR after 2 years of zoledronic acid, continuing monthly treatment reduced progressive bone disease vs observation (HR 0.40, 95% CI 0.16-0.92); raised CTX or TRAcP after stopping flagged risk.
Secondary analysis
Gundesen et al. Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers